Post Content
Sanofi (NASDAQ:SNY) is included among the 10 Best Global Stocks to Buy According to Wall Street Analysts.
Sanofi (NASDAQ:SNY) is a healthcare biopharmaceutical company that engages in the research, development, manufacture, and marketing of therapeutic solutions.
On April 20, BNP Paribas analyst Peter Verdult downgraded Sanofi (NASDAQ:SNY) from ‘Outperform’ to ‘Neutral’, while assigning the stock a price target of $50. The firm cited its revised pipeline assumptions for the downgrade, noting that a “near-term rerating story is unlikely”.
On the other hand, Citi analyst Graham Parry turned slightly more bullish on Sanofi (NASDAQ:SNY) earlier on April 13, raising the firm’s price target on the stock from €80 to €82 (read more details here).
Sanofi (NASDAQ:SNY) projects its sales to grow by a high single-digit percentage in FY 2026, with business EPS surging slightly faster than sales. The company expects this profitable growth to continue for at least five years. Additionally, Sanofi plans to execute a share buyback program of €1B this year.
The strong guidance comes despite Sanofi (NASDAQ:SNY) undergoing a significant change in top leadership this month, with Belén Garijo taking charge as the company’s new CEO on April 29.
While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 8 Best Wind Power and Solar Stocks to Buy Right Now and 10 Best Affordable Blue Chip Stocks to Buy Now
Disclosure: None. Follow Insider Monkey on Google News.